A Phase Ib Multi-Cohort Study of MK-3475 in Subjects With Advanced Solid Tumors
Latest Information Update: 03 May 2023
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Adenocarcinoma; Advanced breast cancer; Gastric cancer; Head and neck cancer; Male breast cancer; Oesophageal cancer; Squamous cell cancer; Triple negative breast cancer; Urogenital cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms KEYNOTE-012
- Sponsors Merck & Co; Merck Sharp & Dohme
- 24 Mar 2023 Results developing the immuno-oncology Qsp platform model assessing efficacy prediction of Pembrolizumab + Enfortumab vedotin (EV) combination in phase II/III clinical trials from Keynote 12 and NCT032885452 studies, presented at the 124th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics.
- 07 Jul 2020 Status changed from active, no longer recruiting to completed.
- 31 May 2020 Results (N=132), assessing radiomic response in recurrent or metastatic head and neck squamous cell cancer patients receiving Pembrolizumab, presented at the 56th Annual Meeting of the American Society of Clinical Oncology